Xultophy: new diabetes drug
Pharmacy Magazine,
1 Min
Xultophy: new diabetes drug
Pharmacy Magazine,
1 Min
In Clinical
Follow this topic
Bookmark
Record learning outcomes
The EC has granted marketing authorisation for Xultophy, which combines once-daily basal insulin degludec and a GLP-1 receptor agonist (liraglutide) in one pen for adults with type 2 diabetes.
Xultophy is added to oral hypoglycaemics when the latter (alone or with basal insulin) do not provide adequate control
Video Player is loading.
Copy Link
Record my learning outcomes
Save for later
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.